There are more patients taking oral anti-diabetic agents including metformin, dipeptidyl peptidase IV inhibitor (DPP4 inhibitor) and sodium-glucose co-transporter 2 inhibitor (SGLT2i) in the obesity group. The gene discussed is DPP4; the disease is obesity disorder.